Retail & Brands
How leading cannabis retailers and brands design, market, and scale in regulated markets.
Retail & Brands · page 2
- Cultivation
De-Risking the Future: What’s Holding Traditional Industry Back from Cannabis Investment?
Nearly a decade after the inception of what we would now consider the ‘global cannabis industry’, Prohibition Partners forecasts its total worth to be around $40bn in 2025, already larger than the entire global recorded music industry.
- Retail & Brands
Canada’s Cannabis Retail Market Reaches C$5.5bn in 2024/25, But Growth Slowing
Canadian adult-use cannabis sales reached C$5.5 billion in the fiscal year ending 31 March 2025, a 6.1% increase on the prior year, according to new data from Statistics Canada, though the pace of growth continued to slow for the third consecutive year.
- Patient Access
Patient Protect Launches to Support UK Medical Cannabis Patients Facing Discrimination
A new UK-wide service supporting medical cannabis patients who face discrimination has launched, as the private sector continues to fill gaps left by the absence of systematic government support.
- Industry Trends
The Scramble for Europe
Last month, the German cannabis market saw its most significant consolidation deal to date, as Canadian heavyweight Organigram announced plans to acquire Sanity Group in a deal worth up to €250m.
- M&A Activity
Curaleaf Laboratories and Sanity Group Announce Partnership to Advance Medical Cannabis Innovation in the UK
Curaleaf Laboratories, one of the UK-leading pharmaceutical-grade medical cannabis manufacturers, is delighted to announce a partnership with Berlin-based Sanity Group, a European life science company focused on cannabinoids and wellbeing products.
- Press releases
Why We Built PPX: From Advocacy to Growth
In 2017, when we launched Prohibition Partners, we set out with the goal to change the conversation around cannabis.
- Investment & Finance
Business Brief: Safe Harbor Capitalises on Rescheduling Momentum with Financial Ecosystem Offering
Cannabis fintech Safe Harbor Financial is positioning itself to capitalise on the regulatory tailwinds created by federal rescheduling, launching new service partnerships and renegotiating core banking agreements in a bid to fill the severe financial infrastructure gap in the US cannabis industry.
- M&A Activity
Business Brief: Argent Biopharma’s Revenues Drop, Outgoings Rise Ahead of AusCann Deal
Argent Biopharma, formerly MGC Pharmaceuticals, has entered 2026 in a precarious financial position, according to its recently published quarterly figures.
- Industry Trends
AI: The Last Refuge of the Failed Cannabis Company
Late last month, NASDAQ-listed cannabis operator Flora Growth, which once operated one of Colombia’s largest outdoor cultivation facilities, became the latest to exit the cannabis industry, rebranding as an AI-focused digital asset firm ZeroStack Corp.
- Industry Trends
Access, Saturation, Consolidation: Why Denmark Foreshadows the Future of Europe’s Medical Cannabis Markets
As Europe’s medical cannabis markets continue to mature, an increasingly familiar pattern is beginning to emerge.
- Prescribers & Clinics
Collapsed Cannim Sees Liquidators Target $32m in Voidable Transactions as UK Creditors Face Enforcement Gap
Collapsed international cannabis operator Cannim has officially been placed into liquidation following a failed sales process, seeing its myriad of creditors vie for their share of the tens of millions of dollars now reportedly outstanding.
- Investment & Finance
From Courtrooms to Boardrooms: 2026 Consolidation Accelerates as Cannabis Companies Merge, Battle and Partner
The global cannabis industry barely had time to catch its breath over the Christmas break, following several seismic developments at the tail end of the year.
